Vision Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Vision Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.99M	Buy	6,699 +104	+2%	+$48.5K	0.38%	50
2025 Q4	$2.99M	Buy	6,595 +29	+0.4%	+$12.5K	0.36%	50
2025 Q3	$2.57M	Sell	6,566 -306	-4%	-$128K	0.32%	54
2025 Q2	$3.06M	Buy	6,872 +307	+5%	+$141K	0.4%	48
2025 Q1	$3.18M	Buy	6,565 +1,541	+31%	+$718K	0.46%	44
2024 Q4	$2.02M	Sell	5,024 -9	-0.2%	-$4.17K	0.3%	58
2024 Q3	$2.34M	Buy	5,033 +292	+6%	+$140K	0.33%	55
2024 Q2	$2.22M	Buy	+4,741	New	+$2.06M	0.33%	57

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vision Capital Management's VRTX Position: Q1 2026 in Review

Vision Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, buying an estimated $48.5K and bringing the position to 6,699 shares worth $2.99M. The position accounts for 0.38% of the portfolio, ranked #50.

Vision Capital Management first reported a position in VRTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.18M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Vision Capital Management held 6,699 shares of Vertex Pharmaceuticals worth $2.99M as of Q1 2026.
Vision Capital Management bought 104 Vertex Pharmaceuticals shares in Q1 2026, an estimated $48.5K.
Vertex Pharmaceuticals made up 0.38% of Vision Capital Management's portfolio in Q1 2026, its #50 holding.
Vision Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Vision Capital Management's Vertex Pharmaceuticals position peaked at $3.18M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Vision Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.